Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfadiazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | AURKA | O14965 | 1/20 | 0.96 |
| ▸ | DHFR | P00374 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | EDNRA | P25101 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfadiazine SCHEMBL11611850 | 1.00 | LMNA (0.96) | LMNAAURKADHFRTSHRSMN1; SMN2 | |
| Sulfadiazine SCHEMBL1486826 | 1.00 | LMNA (0.96) | LMNAAURKADHFRTSHRSMN1; SMN2 | |
| Sulfadiazine SCHEMBL24176 | 0.98 | LMNA (1.00) | LMNAAURKADHFRTSHRSMN1; SMN2 | |
| Sulfadiazine SCHEMBL10422849 | 0.98 | LMNA (1.00) | LMNAAURKADHFRTSHRSMN1; SMN2 | |
| Sulfadiazine SCHEMBL30080807 | 0.98 | LMNA (1.00) | LMNAAURKADHFRTSHRSMN1; SMN2 | |
| Sulfadiazine SCHEMBL6141086 | 0.96 | LMNA (0.96) | LMNAAURKADHFRTSHRSMN1; SMN2 | |
| Sulfadiazine SCHEMBL16860643 | 0.96 | LMNA (0.96) | LMNAAURKADHFRTSHRSMN1; SMN2 | |
| Sulfadiazine SCHEMBL34517 | 0.96 | LMNA (0.96) | LMNAAURKADHFRTSHRSMN1; SMN2 | |
| Sulfadiazine SCHEMBL3728176 | 0.96 | LMNA (0.96) | LMNAAURKADHFRTSHRSMN1; SMN2 | |
| Sulfadiazine SCHEMBL5870705 | 0.96 | LMNA (0.96) | LMNAAURKADHFRTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703116-B2 | Modified macromolecule | STARPHARMA PTY LIMITED (AU) | 2014-04-22 | — | — | US | disclosed |
| US-8445528-B2 | Dendrimer conjugates | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-05-21 | — | — | US | disclosed |
| US-20130116432-A1 | MODIFIED MACROMOLECULE | STARPHARMA PTY LTD (AU) | 2013-05-09 | — | — | US | disclosed |
| US-8337823-B2 | Modified macromolecule | STARPHARMA PTY LIMITED (AU) | 2012-12-25 | — | — | US | disclosed |
| US-20120277376-A1 | DENDRIMER CONJUGATES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-11-01 | — | — | US | disclosed |
| US-8252834-B2 | Dendrimer conjugates | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-08-28 | — | — | US | disclosed |
| US-8163805-B2 | Small molecule antagonists of Bcl-2 family proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-24 | — | — | US | disclosed |
| US-7910621-B2 | Small molecule antagonists of XIAP family proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-03-22 | — | — | US | disclosed |
| EP-1474121-B1 | Synergistic association of (-)- gossypol with docetaxel or paclitaxel for cancer treatment | UNIV MICHIGAN (US) | 2010-07-21 | — | — | EP | disclosed |
| US-20100069344-A1 | SMALL MOLECULE ANTAGONISTS OF BCL2 FAMILY PROTEINS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-03-18 | — | — | US | disclosed |
| EP-1474121-A2 | SMALL MOLECULE ANTAGONISTS OF BCL2 FAMILY PROTEINS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20040214902-A1 | Small molecule antagonists of BCL-2 family proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2004-10-28 | — | — | US | disclosed |
| US-20030199489-A1 | Small molecule inhibitors targeted at BCL-2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2003-10-23 | — | — | US | disclosed |
| WO-2003038060-A2 | SMALL MOLECULE INHIBITORS TARGETED AT BCL-2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-1301211-A2 | MULTIFUNCTIONAL NANODEVICE PLATFORM | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20030008924-A1 | Small molecule antagonists of Bcl-2 family proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2003-01-09 | — | — | US | disclosed |
| WO-2002097053-A2 | SMALL MOLECULE ANTAGONISTS OF BCL2 FAMILY PROTEINS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2002-12-05 | — | — | WO | disclosed |
| US-20020165179-A1 | Multifunctional nanodevice platform | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2002-11-07 | — | — | US | disclosed |
| US-6471968-B1 | DENDRIMER BASED MULTIFUNCTIONAL COMPOSITIONS FOR DISEASE DIAGNOSIS AND THERAPY (E.G. CANCER DIAGNOSIS AND THERAPY); FIRST DENDRIMER IS A POLYAMIDOAMINE (PAMAM) DENDRIMER, SECOND DENDRIMER IS A POLYPROPYLAMINE (POPAM) DENDRIMER | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2002-10-29 | — | — | US | disclosed |
| WO-2001087348-A2 | MULTIFUNCTIONAL NANODEVICE PLATFORM | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214902-A1 | Small molecule antagonists of BCL-2 family proteins | BCL2L1, BCL2, BCL2L2 | LMNA 1912/4885AURKA 4403/4885DHFR 1387/4885 |
| US-20100069344-A1 | SMALL MOLECULE ANTAGONISTS OF BCL2 FAMILY PROTEINS | BCL2L1, BCL2, BCL2L11 | LMNA 2064/4885AURKA 4262/4885DHFR 1523/4885 |
| US-20030199489-A1 | Small molecule inhibitors targeted at BCL-2 | BCL2L1, BCL2, BCL2L2 | LMNA 3640/4885AURKA 2479/4885DHFR 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.